Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 16/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648509 | 0.94 | AVPR1A (0.40) | AVPR1AOXTRIDO1TDO2 | |
| SCHEMBL22648342 | 0.89 | IDO1 (0.39) | AVPR1AOXTRFASNIDO1TDO2 | |
| SCHEMBL22648336 | 0.88 | HRH3 (0.42) | AVPR1AOXTR | |
| SCHEMBL22648475 | 0.83 | AVPR1A (0.44) | AVPR1A | |
| SCHEMBL21138035 | 0.76 | IDO1 (0.52) | AVPR1AOXTRIDO1TDO2 | |
| SCHEMBL22648334 | 0.74 | HSD11B1 (0.44) | IDO1TDO2 | |
| SCHEMBL22648355 | 0.73 | IDO1 (0.52) | AVPR1AIDO1TDO2S1PR5 | |
| SCHEMBL21138032 | 0.72 | IDO1 (0.56) | AVPR1AOXTRFASNIDO1TDO2 | |
| SCHEMBL2158862 | 0.72 | AVPR1A (0.52) | AVPR1AOXTRFASNS1PR5 | |
| SCHEMBL21138037 | 0.72 | IDO1 (0.60) | AVPR1AOXTRIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | AVPR1A 2904/4885OXTR 1945/4885FASN 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.